Niaid preclinical development support - production of GEO-D02 DNA drug product
Ended Awarded Last action
- Contract number
- HHSN27200035
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $835,962
Award facts
- Contract value 100% obligated
- $835,962.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $19,531 | |
| Funding Only Action | $56,401 | |
| Change Order | $251,381 | |
| Change Order | $137,181 | |
| Original award | $371,468 |
About this award
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract, valued at $835,962.00, is for preclinical development support, specifically the production of the GEO-D02 DNA drug product. This is a cost-plus-fixed-fee delivery order contract with a period of performance ending on February 28, 2022. The contract does not have a set-aside designation.
ABL is a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The company has been awarded numerous federal contracts and grants, particularly from the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), to advance the development of medical countermeasures for various infectious diseases and other health conditions. This contract is part of ABL's broader work supporting preclinical and clinical development programs for the NIAID.
Quick answers
Who was awarded contract HHSN27200035?
HHSN27200035 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 9, 2016.
How much is contract HHSN27200035 worth?
The government has obligated $835,962 on HHSN27200035.
Is contract HHSN27200035 an order under another contract?
Yes. HHSN27200035 is a delivery order under HHSN272201100021I, an indefinite delivery contract.
Was contract HHSN27200035 competed?
The extent of competition for HHSN27200035 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award